Overexpression of hSNF2H in glioma promotes cell proliferation, invasion, and chemoresistance through its interaction with Rsf-1

Tumor Biology

Volumn 37, Issue 6, 2016, Pages 7203-7212

  Zhao, Xiao Chun ^a   An, Ping ^a   Wu, Xiu Ying ^a   Zhang, Li Min ^b   Long, Bo ^a   Tian, Yue ^a   Chi, Xiao Ying ^c   Tong, Dong Yi ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CANGZHOU CENTRAL HOSPITAL   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Glioma; hSNF2H; Invasion; Proliferation

Indexed keywords

CYCLIN D1; CYCLIN E; GELATINASE A; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR PROTEIN; PROTEIN BCL 2; PROTEIN HSNF2H; PROTEIN RSF 1; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; ALKYLATING AGENT; DACARBAZINE; MESSENGER RNA; NONHISTONE PROTEIN; RSF1 PROTEIN, HUMAN; SMARCA5 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INHIBITION; CELL CYCLE CHECKPOINT; CELL INVASION; CELL INVASION ASSAY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG PROTEIN BINDING; DRUG TARGETING; FEMALE; GLIOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MTT ASSAY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; CELL CYCLE; CELL MOTION; DRUG RESISTANCE; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CHROMOSOMAL PROTEINS, NON-HISTONE; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MALE; MIDDLE AGED; NEOPLASM GRADING; NUCLEAR PROTEINS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 84949815235     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4579-4     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62:10–29.
2. Krupkova Jr O, Loja T, Redova M, Neradil J, Zitterbart K, et al. Analysis of nuclear nestin localization in cell lines derived from neurogenic tumors. Tumour Biol. 2011;32:631–9.
3. Zadran S, Amighi A, Otiniano E, Wong K, Zadran H. ENTPD5-mediated modulation of ATP results in altered metabolism and decreased survival in gliomablastoma multiforme. Tumour Biol. 2012;33:2411–21.
4. Kokavec J, Podskocova J, Zavadil J, Stopka T. Chromatin remodeling and SWI/SNF2 factors in human disease. Front Biosci. 2008;13:6126–34.
5. LeRoy G, Orphanides G, Lane WS, Reinberg D. Requirement of RSF and FACT for transcription of chromatin templates in vitro. Science. 1998;282:1900–4.
6. Poot RA, Dellaire G, Hulsmann BB, Grimaldi MA, Corona DF, et al. HuCHRAC, a human ISWI chromatin remodelling complex contains hACF1 and two novel histone-fold proteins. EMBO J. 2000;19:3377–87.
7. Strohner R, Nemeth A, Jansa P, Hofmann-Rohrer U, Santoro R, et al. NoRC--a novel member of mammalian ISWI-containing chromatin remodeling machines. EMBO J. 2001;20:4892–900.
8. Lazzaro MA, Picketts DJ. Cloning and characterization of the murine Imitation Switch (ISWI) genes: differential expression patterns suggest distinct developmental roles for Snf2h and Snf2l. J Neurochem. 2001;77:1145–56.
9. Chong S, Vickaryous N, Ashe A, Zamudio N, Youngson N, et al. Modifiers of epigenetic reprogramming show paternal effects in the mouse. Nat Genet. 2007;39:614–22.
10. Stopka T, Skoultchi AI. The ISWI ATPase Snf2h is required for early mouse development. Proc Natl Acad Sci U S A. 2003;100:14097–102.
11. Gigek CO, Lisboa LC, Leal MF, Silva PN, Lima EM, et al. SMARCA5 methylation and expression in gastric cancer. Cancer Invest. 2011;29:162–6.
12. Stopka T, Zakova D, Fuchs O, Kubrova O, Blafkova J, et al. Chromatin remodeling gene SMARCA5 is dysregulated in primitive hematopoietic cells of acute leukemia. Leukemia. 2000;14:1247–52.
13. Reis ST, Timoszczuk LS, Pontes-Junior J, Viana N, Silva IA, et al. The role of micro RNAs let7c, 100 and 218 expression and their target RAS, C-MYC, BUB1, RB, SMARCA5, LAMB3 and Ki-67 in prostate cancer. Clinics (Sao Paulo). 2013;68:652–7.
14. Sheu JJ, Choi JH, Yildiz I, Tsai FJ, Shaul Y, et al. The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. Cancer Res. 2008;68:4050–7.
15. Sheu JJ, Guan B, Choi JH, Lin A, Lee CH, et al. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem. 2010;285:38260–9.
16. Loyola A, Huang JY, LeRoy G, Hu S, Wang YH, et al. Functional analysis of the subunits of the chromatin assembly factor RSF. Mol Cell Biol. 2003;23:6759–68.
17. Li H, Zhang Y, Zhang Y, Bai X, Peng Y, et al. Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker. Tumour Biol. 2014;35:5771–6.
18. Lin CY, Tian YF, Wu LC, Chen LT, Lin LC, et al. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation. J Clin Pathol. 2012;65:687–92.
19. Liu S, Dong Q, Wang E. Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer. Tumour Biol. 2012;33:1485–91.
20. Choi JH, Sheu JJ, Guan B, Jinawath N, Markowski P, et al. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res. 2009;69:1407–15.
21. Qi XC, Xie DJ, Yan QF, Wang YR, Zhu YX, et al. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2. Biochem Biophys Res Commun. 2013;437:565–72.
22. Wagner L, Marschall V, Karl S, Cristofanon S, Zobel K, et al. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-kappaB-dependent manner. Oncogene. 2013;32:988–97.
23. Liu S, Shen H, Xu M, Liu O, Zhao L, et al. FRP inhibits ox-LDL-induced endothelial cell apoptosis through an Akt-NF-{kappa}B-Bcl-2 pathway and inhibits endothelial cell apoptosis in an apoE-knockout mouse model. Am J Physiol Endocrinol Metab. 2010;299:E351–363.
24. Chen GG, Liang NC, Lee JF, Chan UP, Wang SH, et al. Over-expression of Bcl-2 against Pteris semipinnata L-induced apoptosis of human colon cancer cells via a NF-kappa B-related pathway. Apoptosis. 2004;9:619–27.
25. Zhou AY, Shen RR, Kim E, Lock YJ, Xu M, et al. IKKepsilon-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Rep. 2013;3:724–33.
26. Sheu JJ, Choi JH, Guan B, Tsai FJ, Hua CH, et al. Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. J Pathol. 2013;229:559–68.